Product: buPROPion HCl Extended-Release Tablets,   USP (SR), 150 mg ,a) 60 count (NDC 69097-878-03)  and b) 100 count (NDC 69097-878-07) bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788
Reason for recall: Failed Dissolution Specifications; during stability testing
Recall initiated: 20180315
Status: Terminated
Classification: Class III
Recall type: Voluntary: Firm initiated